Magenta Therapeutics Inc banner
M

Magenta Therapeutics Inc
F:3MT

Watchlist Manager
Magenta Therapeutics Inc
F:3MT
Watchlist
Price: 11.136 EUR 0.29% Market Closed
Market Cap: €368.6m

Relative Value

There is not enough data to reliably calculate the relative value of 3MT.

Relative Value is the estimated value of a stock based on various valuation multiples like P/E and EV/EBIT ratios. It offers a quick snapshot of a stock's valuation in relation to its peers and historical norms.

3MT Relative Value
Base Case
Not Available
M
Worst Case
Base Case
Best Case

Multiples Across Competitors

3MT Competitors Multiples
Magenta Therapeutics Inc Competitors

All Multiples
P/S
P/E
EV/EBITDA
EV/EBIT
All Countries
Close
Market Cap P/S P/E EV/EBITDA EV/EBIT
US
Magenta Therapeutics Inc
F:3MT
368.6m EUR 0 -5.7 -4.3 -4.3
FR
Pharnext SCA
OTC:PNEXF
6T USD 33 643 258.8 -159 901.4 -194 171.3 -191 955.6
US
Abbvie Inc
NYSE:ABBV
395.5B USD 6.6 168.3 16.3 23.1
US
Amgen Inc
NASDAQ:AMGN
198.2B USD 5.4 25.5 14.7 14.7
US
Gilead Sciences Inc
NASDAQ:GILD
184.1B USD 6.3 22.7 15.4 15.4
US
Vertex Pharmaceuticals Inc
NASDAQ:VRTX
118.1B USD 10.1 32.1 23.6 24.6
US
Epizyme Inc
F:EPE
94.1B EUR 2 094 -534.3 -581.8 -566.3
US
Regeneron Pharmaceuticals Inc
NASDAQ:REGN
79.5B USD 5.5 17.7 14.9 17
AU
CSL Ltd
ASX:CSL
73B AUD 3.5 18 12.2 15.2
NL
argenx SE
XBRU:ARGX
43.4B EUR 14.3 33.7 57.5 59.1
US
Seagen Inc
F:SGT
39.3B EUR 20.2 -61.8 -66.7 -60.2
P/S Multiple
Revenue Growth P/S to Growth
US
M
Magenta Therapeutics Inc
F:3MT
Average P/S: 3 364 542.5
Not Available
N/A N/A
FR
Pharnext SCA
OTC:PNEXF
33 643 258.8
N/A N/A
US
Abbvie Inc
NYSE:ABBV
6.6
9%
0.7
US
Amgen Inc
NASDAQ:AMGN
5.4
2%
2.7
US
Gilead Sciences Inc
NASDAQ:GILD
6.3
4%
1.6
US
Vertex Pharmaceuticals Inc
NASDAQ:VRTX
10.1
10%
1
US
E
Epizyme Inc
F:EPE
2 094
N/A N/A
US
Regeneron Pharmaceuticals Inc
NASDAQ:REGN
5.5
9%
0.6
AU
CSL Ltd
ASX:CSL
3.5
5%
0.7
NL
argenx SE
XBRU:ARGX
14.3
49%
0.3
US
S
Seagen Inc
F:SGT
20.2
30%
0.7
P/E Multiple
Earnings Growth PEG
US
M
Magenta Therapeutics Inc
F:3MT
Average P/E: 45.4
Negative Multiple: -5.7
N/A N/A
FR
Pharnext SCA
OTC:PNEXF
Negative Multiple: -159 901.4 N/A N/A
US
Abbvie Inc
NYSE:ABBV
168.3
89%
1.9
US
Amgen Inc
NASDAQ:AMGN
25.5
18%
1.4
US
Gilead Sciences Inc
NASDAQ:GILD
22.7
192%
0.1
US
Vertex Pharmaceuticals Inc
NASDAQ:VRTX
32.1
N/A N/A
US
E
Epizyme Inc
F:EPE
Negative Multiple: -534.3 N/A N/A
US
Regeneron Pharmaceuticals Inc
NASDAQ:REGN
17.7
13%
1.4
AU
CSL Ltd
ASX:CSL
18
11%
1.6
NL
argenx SE
XBRU:ARGX
33.7
42%
0.8
US
S
Seagen Inc
F:SGT
Negative Multiple: -61.8 N/A N/A
EV/EBITDA Multiple
EBITDA Growth EV/EBITDA to Growth
US
M
Magenta Therapeutics Inc
F:3MT
Average EV/EBITDA: 22.1
Negative Multiple: -4.3
N/A N/A
FR
Pharnext SCA
OTC:PNEXF
Negative Multiple: -194 171.3 N/A N/A
US
Abbvie Inc
NYSE:ABBV
16.3
14%
1.2
US
Amgen Inc
NASDAQ:AMGN
14.7
10%
1.5
US
Gilead Sciences Inc
NASDAQ:GILD
15.4
7%
2.2
US
Vertex Pharmaceuticals Inc
NASDAQ:VRTX
23.6
16%
1.5
US
E
Epizyme Inc
F:EPE
Negative Multiple: -581.8 N/A N/A
US
Regeneron Pharmaceuticals Inc
NASDAQ:REGN
14.9
24%
0.6
AU
CSL Ltd
ASX:CSL
12.2
8%
1.5
NL
argenx SE
XBRU:ARGX
57.5
810%
0.1
US
S
Seagen Inc
F:SGT
Negative Multiple: -66.7 N/A N/A
EV/EBIT Multiple
EBIT Growth EV/EBIT to Growth
US
M
Magenta Therapeutics Inc
F:3MT
Average EV/EBIT: 24.2
Negative Multiple: -4.3
N/A N/A
FR
Pharnext SCA
OTC:PNEXF
Negative Multiple: -191 955.6 N/A N/A
US
Abbvie Inc
NYSE:ABBV
23.1
30%
0.8
US
Amgen Inc
NASDAQ:AMGN
14.7
2%
7.3
US
Gilead Sciences Inc
NASDAQ:GILD
15.4
13%
1.2
US
Vertex Pharmaceuticals Inc
NASDAQ:VRTX
24.6
16%
1.5
US
E
Epizyme Inc
F:EPE
Negative Multiple: -566.3 N/A N/A
US
Regeneron Pharmaceuticals Inc
NASDAQ:REGN
17
23%
0.7
AU
CSL Ltd
ASX:CSL
15.2
11%
1.4
NL
argenx SE
XBRU:ARGX
59.1
N/A N/A
US
S
Seagen Inc
F:SGT
Negative Multiple: -60.2 N/A N/A